mTOR inhibitors, mycophenolates, and other immunosuppression regimens on antibody response to SARS-CoV-2 mRNA vaccines in solid organ transplant recipients
Sunjae Bae(New York University), Dorry L. Segev(New York University), Linda W. Moore(Methodist Hospital), Howard J. Huang(Houston Methodist), R. Mark Ghobrial(Methodist Hospital), Teresa Po‐Yu Chiang(Johns Hopkins University), Ashrith Guha(Houston Methodist), William A. Werbel(Johns Hopkins University), Aaron A.R. Tobian(Johns Hopkins University), Jennifer L. Alejo(Johns Hopkins University), A. Osama Gaber(Methodist Hospital), Richard J. Knight(Methodist Hospital), Mara McAdams‐DeMarco(New York University)
Cited by 21
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863